
CLAIMS

1. A COMPOUND OF FORMULA (J):



(J),

or a pharmaceutically acceptable salt thereof,

wherein

X is O or NR^4;

ring A is a phenyl or heteroaryl;

ring B is a phenyl or heteroaryl;

each R^1 is independently C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, C_1-C_6 hydroxyalkyl, C_2-C_6 alkoxyalkyl, halogen, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, $-C(O)R^{1a}$, $-C(O)OR^{1a}$, $-OC(O)R^{1a}$, $-C(O)N(R^{1a})(R^{1b})$, $-N(R^{1a})C(O)(R^{1b})$, $-OC(O)N(R^{1a})(R^{1b})$, $-N(R^{1a})C(O)(OR^{1b})$, $-S(O)R^{1a}$, $-S(O)_2R^{1a}$, $-S(O)_2N(R^{1a})(R^{1b})$, $-S(O)(NH)R^{1a}$, $-S(O)(NH)N(R^{1a})(R^{1b})$, $-N(R^{1a})(R^{1b})$, -OH, -CN, $-NO_2$, C_3-C_8 cycloalkyl, (C_1-C_3 alkyl)(C_3-C_8 cycloalkyl), -O-(C_3-C_8 cycloalkyl), heterocycloalkyl, (C_1-C_3 alkyl)(heterocycloalkyl), -O-(heterocycloalkyl), C_6-C_{10} aryl, (C_1-C_3 alkyl)(C_6-C_{10} aryl), -O-(C_6-C_{10} aryl), heteroaryl, (C_1-C_3 alkyl)(heteroaryl), or –O-(heteroaryl), wherein each alkyl is substituted with 0, 1, 2, 3, 4, 5, or 6 R^{1c}, each alkoxy and alkynyl is substituted with 0, 1, 2, or 3 R^{1d}, and each cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is substituted with 0, 1, 2, or 3 R^{1e};

each R^{1a} and R^{1b} is independently hydrogen or C_1-C_6 alkyl;

each R^{1c} is independently C_1-C_6 alkoxy, halogen, C_1-C_6 haloalkoxy, $-NR^{1c1}R^{1c2}$, -OH, or -CN;

each R^{1c1} and R^{1c2} is independently hydrogen or C_1-C_6 alkyl;

each R^{1d} is independently deuterium, C_3-C_8 cycloalkyl, heterocycloalkyl, C_6-C_{10} aryl, or heteroaryl;

each R^{1e} is independently C_1-C_6 alkyl, C_1-C_6 alkoxy, halogen, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, -OH, or -CN;

alternatively, two R^1 groups on adjacent carbons together with the atoms to which they are attached combine to form a C_5-C_8 cycloalkyl or a heterocycloalkyl substituted with 0, 1, 2, 3, 4, 5, or 6 halogen, C_1-C_4 alkyl, -OH or -CN;

L is –C_1-C_4 alkylene-, –(C_1-C_4 alkylene)-O-, or –O-;

R^2 is a heteroaryl, which is substituted with 0, 1, 2, 3, or 4 R^{2a};

each R^{2a} is independently C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, C_1-C_6 hydroxyalkyl, C_2-C_6 alkoxyalkyl, halogen, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, -C(O)R^{2b}, -C(O)OR^{2b}, -OC(O)R^{2b}, -C(O)N(R^{2b})(R^{2c}), -N(R^{2b})C(O)(R^{2c}), -S(O)$_2$$R^{2b}$, -S(O)$_2$N($R^{2b}$)($R^{2c}$), -N($R^{2b}$)($R^{2c}$), -OH, -CN, or –$NO_2$;

each R^{2b} and R^{2c} is independently hydrogen or C_1-C_6 alkyl;

each R^3 is independently C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, C_1-C_6 hydroxyalkyl, C_2-C_6 alkoxyalkyl, halogen, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, -C(O)R^{3a}, -C(O)OR^{3a}, -OC(O)R^{3a}, -C(O)N(R^{3a})(R^{3b}), -N(R^{3a})C(O)(R^{3b}), -OC(O)N(R^{3a})(R^{3b}), -N(R^{3a})C(O)(OR^{3b}), -S(O)R^{3a}, -S(O)$_2$$R^{3a}$, -S(O)$_2$N($R^{3a}$)($R^{3b}$), -S(O)(NH)$R^{3a}$, -S(O)(NH)N($R^{3a}$)($R^{3b}$), -N($R^{3a}$)($R^{3b}$), OH, -CN, -$NO_2$, C_3-C_8 cycloalkyl, (C_1-C_3 alkyl)(C_3-C_8 cycloalkyl), -O-(C_3-C_8 cycloalkyl), heterocycloalkyl, (C_1-C_3 alkyl)(heterocycloalkyl), -O-(heterocycloalkyl), C_6-C_{10} aryl, (C_1-C_3 alkyl)(C_6-C_{10} aryl), -O-(C_6-C_{10} aryl), heteroaryl, (C_1-C_3 alkyl)(heteroaryl), or –O-(heteroaryl), wherein each alkyl is substituted with 0, 1, 2, 3, 4, 5, or 6 R^{3c}, each alkoxy is substituted with 0, 1, 2, or 3 R^{3d}, and each cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is substituted with 0, 1, 2, or 3 R^{3e}; or,

two R^3 on the same carbon atom together represent an oxo group;

each R^{3a} and R^{3b} is independently hydrogen or C_1-C_6 alkyl;

each R^{3c} is independently C_1-C_6 alkoxy, halogen, C_1-C_6 haloalkoxy, -N$R^{3c1}$$R^{3c2}$, OH, or -CN;

each R^{3c1} and R^{3c2} is independently hydrogen or C_1-C_6 alkyl;

each R^{3d} is independently C_3-C_8 cycloalkyl, heterocycloalkyl, phenyl, or heteroaryl;

each R^{3e} is independently C_1-C_6 alkyl, C_1-C_6 alkoxy, halogen, C_1-C_6 haloalkyl, or C_1-C_6 haloalkoxy;

R^4 is hydrogen or C_1-C_6 alkyl;

subscript n is 0, 1, 2, 3, or 4; and


subscript q is 0, 1, 2, 3, or 4;

wherein

each heterocycloalkyl is a 3- to 8-membered ring that includes 1 to 4 heteroatoms each independently N, O or S; and

each heteroaryl is a 5- to 6-membered ring that includes 1 to 4 heteroatoms each independently N, O or S.

2. The compound of claim 1, having Formula (I):



(I),

or a pharmaceutically acceptable salt thereof,

wherein

each R^1 is independently C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, C_1-C_6 hydroxyalkyl, C_2-C_6 alkoxyalkyl, halogen, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, -$C(O)R^{1a}$, -$C(O)OR^{1a}$, -$OC(O)R^{1a}$, -$C(O)N(R^{1a})(R^{1b})$, -$N(R^{1a})C(O)(R^{1b})$, -$OC(O)N(R^{1a})(R^{1b})$, -$N(R^{1a})C(O)(OR^{1b})$, -$S(O)R^{1a}$, -$S(O)_2R^{1a}$, -$S(O)_2N(R^{1a})(R^{1b})$, -$S(O)(NH)R^{1a}$, -$S(O)(NH)N(R^{1a})(R^{1b})$, -$N(R^{1a})(R^{1b})$, OH, -CN, -$NO_2$, C_3-C_8 cycloalkyl, (C_1-C_3 alkyl)(C_3-C_8 cycloalkyl), -O-(C_3-C_8 cycloalkyl), heterocycloalkyl, (C_1-C_3 alkyl)(heterocycloalkyl), -O-(heterocycloalkyl), C_6-C_{10} aryl, (C_1-C_3 alkyl)(C_6-C_{10} aryl), -O-(C_6-C_{10} aryl), heteroaryl, (C_1-C_3 alkyl)(heteroaryl), or –O-(heteroaryl), wherein each alkyl is substituted with 0, 1, 2, 3, 4, 5, or 6 R^{1c}, each alkoxy and alkynyl is substituted with 0, 1, 2, or 3 R^{1d}, and each cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is substituted with 0, 1, 2, or 3 R^{1e};

each R^{1a} and R^{1b} is independently hydrogen or C_1-C_6 alkyl;

each R^{1c} is independently C_1-C_6 alkoxy, halogen, C_1-C_6 haloalkoxy, -$NR^{1c1}R^{1c2}$, -OH, or -CN;

each R^{1c1} and R^{1c2} is independently hydrogen or C_1-C_6 alkyl;

each R^{1d} is independently deuterium, C_3-C_8 cycloalkyl, heterocycloalkyl, C_6-C_{10} aryl, or heteroaryl;

each R^{1e} is independently C_1-C_6 alkyl, C_1-C_6 alkoxy, halogen, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, -OH, or -CN;

alternatively, two R^1 groups on adjacent carbons together with the atoms to which they are attached combine to form a C_5-C_8 cycloalkyl or a heterocycloalkyl substituted with 0, 1, 2, 3, 4, 5, or 6 halogen, C_1-C_4 alkyl, -OH or -CN;

L is –C_1-C_4 alkylene-, –(C_1-C_4 alkylene)-O-, or –O-;

R^2 is a heteroaryl, which is substituted with 0, 1, 2, 3, or 4 R^{2a};

each R^{2a} is independently C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, C_1-C_6 hydroxyalkyl, C_2-C_6 alkoxyalkyl, halogen, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, -C(O)R^{2b}, -C(O)OR^{2b}, -OC(O)R^{2b}, -C(O)N(R^{2b})(R^{2c}), -N(R^{2b})C(O)(R^{2c}), -S(O)$_2$$R^{2b}$, -S(O)$_2$N($R^{2b}$)($R^{2c}$), -N($R^{2b}$)($R^{2c}$), OH, -CN, or –$NO_2$;

each R^{2b} and R^{2c} is independently hydrogen or C_1-C_6 alkyl;

each R^3 is independently C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, C_1-C_6 hydroxyalkyl, C_2-C_6 alkoxyalkyl, halogen, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, -C(O)R^{3a}, -C(O)OR^{3a}, -OC(O)R^{3a}, -C(O)N(R^{3a})(R^{3b}), -N(R^{3a})C(O)(R^{3b}), -OC(O)N(R^{3a})(R^{3b}), -N(R^{3a})C(O)(OR^{3b}), -S(O)R^{3a}, -S(O)$_2$$R^{3a}$, -S(O)$_2$N($R^{3a}$)($R^{3b}$), -S(O)(NH)$R^{3a}$, -S(O)(NH)N($R^{3a}$)($R^{3b}$), -N($R^{3a}$)($R^{3b}$), OH, -CN, -$NO_2$, C_3-C_8 cycloalkyl, (C_1-C_3 alkyl)(C_3-C_8 cycloalkyl), -O-(C_3-C_8 cycloalkyl), heterocycloalkyl, (C_1-C_3 alkyl)(heterocycloalkyl), -O-(heterocycloalkyl), C_6-C_{10} aryl, (C_1-C_3 alkyl)(C_6-C_{10} aryl), -O-(C_6-C_{10} aryl), heteroaryl, (C_1-C_3 alkyl)(heteroaryl), or –O-(heteroaryl), wherein each alkyl is substituted with 0, 1, 2, 3, 4, 5, or 6 R^{3c}, each alkoxy is substituted with 0, 1, 2, or 3 R^{3d}, and each cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is substituted with 0, 1, 2, or 3 R^{3e}; or,

two R^3 on the same carbon atom together represent an oxo group;

each R^{3a} and R^{3b} is independently hydrogen or C_1-C_6 alkyl;

each R^{3c} is independently C_1-C_6 alkoxy, halogen, C_1-C_6 haloalkoxy, -N$R^{3c1}$$R^{3c2}$, -OH, or -CN;

each R^{3c1} and R^{3c2} is independently hydrogen or C_1-C_6 alkyl;

each R^{3d} is independently C_3-C_8 cycloalkyl, heterocycloalkyl, phenyl, or heteroaryl;

each R^{3e} is independently C_1-C_6 alkyl, C_1-C_6 alkoxy, halogen, C_1-C_6 haloalkyl, or C_1-C_6 haloalkoxy;

subscript n is 0, 1, 2, 3, or 4; and

subscript q is 0, 1, 2, 3, or 4;

wherein

each heterocycloalkyl is a 3- to 8-membered ring that includes 1 to 4 heteroatoms each independently N, O or S; and

each heteroaryl is a 5- to 6-membered ring that includes 1 to 4 heteroatoms each independently N, O or S.

3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein

each R^1 is independently C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 hydroxyalkyl, C_2-C_6 alkoxyalkyl, halogen, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, OH, -CN, C_3-C_8 cycloalkyl, (C_1-C_3 alkyl)(C_3-C_8 cycloalkyl), -O-(C_3-C_8 cycloalkyl), heterocycloalkyl, (C_1-C_3 alkyl)(heterocycloalkyl), -O-(heterocycloalkyl), C_6-C_{10} aryl, or heteroaryl, wherein each alkyl is substituted with 0, 1, 2, or 3 R^{1c}, and each alkoxy and alkynyl is substituted with 0, 1, 2, or 3 R^{1d}; or

alternatively, two R^1 on adjacent carbons together with the atoms to which they are attached combine to form a C_5-C_8 cycloalkyl or a heterocycloalkyl.


4. The compound of claim 2 or claim 3, or a pharmaceutically acceptable salt thereof, wherein













L is $–CH_2$-, $–CH_2O$-, or –O-.












5. The compound of any one of claims 2 to 4, or a pharmaceutically acceptable salt thereof, wherein











each R^3 is independently C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 hydroxyalkyl, C_2-C_6 alkoxyalkyl, halogen, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, -C(O)R^{3a}, -C(O)OR^{3a}, -OC(O)R^{3a}, -C(O)N(R^{3a})(R^{3b}), -N(R^{3a})C(O)(R^{3b}), -S(O)$_2$$R^{3a}$, -S(O)$_2$N($R^{3a}$)($R^{3b}$), -OH, -CN, C_3-C_8 cycloalkyl, or heterocycloalkyl.











6. The compound of any one of claims 2 to 5, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the following compounds:











No.	Structure	Name
1		4-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxyphenyl)sulfonyl)-2-methoxybenzamide










No.	Structure	Name
2		4-((1H-pyrazol-1-yl)methyl)-2-methoxy-N-((2-methoxyphenyl)sulfonyl)benzamide
3		4-((1H-pyrazol-1-yl)methyl)-N-((5-ethyl-2-methoxyphenyl)sulfonyl)-2-methoxybenzamide
4		4-((1H-pyrazol-1-yl)methyl)-N-((5-(tert-butyl)-2-methoxyphenyl)sulfonyl)-2-methoxybenzamide
5		4-((1H-pyrazol-1-yl)methyl)-2-methoxy-N-((6-methoxy-2,3-dihydro-1H-inden-5-yl)sulfonyl)benzamide
6		3-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxyphenyl)sulfonyl)-5-methoxybenzamide
7		4-((1H-pyrazol-1-yl)methyl)-N-((5-(tert-butyl)-2-methoxyphenyl)sulfonyl)-2-fluorobenzamide
8		4-((1H-pyrazol-1-yl)methyl)-N-((4-(tert-butyl)-2-methoxyphenyl)sulfonyl)-3-methoxybenzamide
9		5-((1H-pyrazol-1-yl)methyl)-N-((5-(tert-butyl)-2-methoxyphenyl)sulfonyl)-2-methoxybenzamide
10		4-((1H-pyrazol-1-yl)methyl)-2-methoxy-N-((2-methoxy-4-(1H-pyrazol-1-yl)phenyl)sulfonyl)benzamide
11		4-((1H-pyrazol-1-yl)methyl)-N-((4-(tert-butyl)-2-methoxyphenyl)sulfonyl)-2-methoxybenzamide
12		4-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxyphenyl)sulfonyl)-3-fluorobenzamide
13		4-((1H-pyrazol-1-yl)methyl)-N-((5-(tert-butyl)-2-methoxyphenyl)sulfonyl)-3-fluorobenzamide










No.	Structure	Name
14		4-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxyphenyl)sulfonyl)-3-methoxybenzamide
15		4-((1H-pyrazol-1-yl)methyl)-2-methoxy-N-((3-methoxy-5,6,7,8-tetrahydronaphthalen-2-yl)sulfonyl)benzamide
16		4-((1H-pyrazol-1-yl)methyl)-3-bromo-N-((5-(tert-butyl)-2-methoxyphenyl)sulfonyl)benzamide
17		4-((1H-pyrazol-1-yl)methyl)-N-((5-(tert-butyl)-2-methoxyphenyl)sulfonyl)-3-cyclopropylbenzamide
18		4-((1H-pyrazol-1-yl)methyl)-N-((5-(tert-butyl)-2-methoxyphenyl)sulfonyl)-3-cyanobenzamide
19		4-((1H-pyrazol-1-yl)methyl)-3-methoxy-N-((2-methoxy-5-(1H-pyrazol-1-yl)phenyl)sulfonyl)benzamide
20		4-((1H-pyrazol-1-yl)methyl)-N-((5-(tert-butyl)-2-methoxyphenyl)sulfonyl)-3-methylbenzamide
21		4-((1H-pyrazol-1-yl)methyl)-N-((5-(tert-butyl)-2-methoxyphenyl)sulfonyl)-3-ethoxybenzamide
22		4-((1H-pyrazol-1-yl)methyl)-N-([1,1'-biphenyl]-2-ylsulfonyl)-3-methoxybenzamide
23		4-((1H-pyrazol-1-yl)methyl)-N-((3-hydroxyphenyl)sulfonyl)-3-methoxybenzamide
24		4-((1H-pyrazol-1-yl)methyl)-N-((5-bromo-2-methoxyphenyl)sulfonyl)-3-methoxybenzamide





No.	Structure	Name
25		4-((1H-pyrazol-1-yl)methyl)-N-((5-(tert-butyl)-2-methoxyphenyl)sulfonyl)-3-(trifluoromethyl)benzamide
26		4-((1H-pyrazol-1-yl)methyl)-3-methoxy-N-((2-methoxyphenyl)sulfonyl)benzamide
27		4-((1H-pyrazol-1-yl)methyl)-3-methoxy-N-((6-methoxy-2,3-dihydro-1H-inden-5-yl)sulfonyl)benzamide
28		4-((1H-pyrazol-1-yl)methyl)-3-cyclopropyl-N-((2,6-dimethoxyphenyl)sulfonyl)benzamide
29		4-((1H-pyrazol-1-yl)methyl)-N-((5-cyclopropyl-2-methoxyphenyl)sulfonyl)-3-methoxybenzamide
30		4-((1H-pyrazol-1-yl)methyl)-N-((5-ethyl-2-methoxyphenyl)sulfonyl)-3-methoxybenzamide
31		4-((1H-pyrazol-1-yl)methyl)-3-methoxy-N-((2-methoxy-4-(trifluoromethyl)phenyl)sulfonyl)benzamide
32		4-((1H-pyrazol-1-yl)methyl)-3-methoxy-N-((2-methoxy-5-(trifluoromethyl)phenyl)sulfonyl)benzamide
33		4-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxyphenyl)sulfonyl)-3-(trifluoromethoxy)benzamide
34		4-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxyphenyl)sulfonyl)-3-methylbenzamide

No.	Structure	Name
35		4-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxyphenyl)sulfonyl)-3-(trifluoromethyl)benzamide
36		4-((1H-pyrazol-1-yl)methyl)-3-methoxy-N-((2-methoxy-6-(1H-pyrazol-1-yl)phenyl)sulfonyl)benzamide
37		4-((1H-pyrazol-1-yl)methyl)-3-(difluoromethoxy)-N-((2,6-dimethoxyphenyl)sulfonyl)benzamide
38		4-((1H-pyrazol-1-yl)methyl)-3-methoxy-N-((6-methoxy-2,3-dihydrobenzofuran-7-yl)sulfonyl)benzamide
39		4-((1H-pyrazol-1-yl)methyl)-N-((5-hydroxy-2-methoxyphenyl)sulfonyl)-3-methoxybenzamide
40		4-((1H-pyrazol-1-yl)methyl)-3-cyclopropyl-N-((2,6-dimethoxyphenyl)sulfonyl)-2-fluorobenzamide
41		4-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxyphenyl)sulfonyl)-2,3-dimethoxybenzamide
42		4-((1H-pyrazol-1-yl)methyl)-N-((2,4-dimethoxyphenyl)sulfonyl)-3-methoxybenzamide
43		4-((1H-pyrazol-1-yl)methyl)-N-((5-fluoro-2,4-dimethoxyphenyl)sulfonyl)-3-methoxybenzamide
44		4-((1H-pyrazol-1-yl)methyl)-N-((5-chloro-2,4-dimethoxyphenyl)sulfonyl)-3-methoxybenzamide

No.	Structure	Name
45		4-((1H-pyrazol-1-yl)methyl)-N-((5-bromo-2,4-dimethoxyphenyl)sulfonyl)-3-methoxybenzamide
46		4-((1H-pyrazol-1-yl)methyl)-N-((3-chloro-2,6-dimethoxyphenyl)sulfonyl)-3-methoxybenzamide
47		4-((1H-pyrazol-1-yl)methyl)-3-methoxy-N-((2,4,6-trimethoxyphenyl)sulfonyl)benzamide
48		4-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxyphenyl)sulfonyl)-2,5-dimethoxybenzamide
49		4-((1H-pyrazol-1-yl)methyl)-3-bromo-N-((2,6-dimethoxyphenyl)sulfonyl)-2-fluorobenzamide
50		N-((2,6-dimethoxyphenyl)sulfonyl)-3-methoxy-4-((pyrimidin-2-yloxy)methyl)benzamide
51		4-((1H-pyrazol-1-yl)methyl)-N-((2-(difluoromethoxy)phenyl)sulfonyl)-3-methoxybenzamide
52		4-((1H-pyrazol-1-yl)methyl)-N-((2-cyclopropoxy-6-methoxyphenyl)sulfonyl)-3-methoxybenzamide
53		4-((1H-pyrazol-1-yl)methyl)-3-methoxy-N-((2-(pyridin-2-ylmethoxy)phenyl)sulfonyl)benzamide
54		4-((1H-pyrazol-1-yl)methyl)-N-((5-(2-hydroxypropan-2-yl)-2-methoxyphenyl)sulfonyl)-3-methoxybenzamide


No.	Structure	Name
55		4-((1H-pyrazol-1-yl)methyl)-N-((2-isopropoxy-6-methoxyphenyl)sulfonyl)-3-methoxybenzamide
56		4-((1H-pyrazol-1-yl)methyl)-3-methoxy-N-((5-methoxy-2,3-dihydro-1H-inden-4-yl)sulfonyl)benzamide
57		4-((1H-pyrazol-1-yl)methyl)-3-methoxy-N-((2-methoxy-5,6,7,8-tetrahydronaphthalen-1-yl)sulfonyl)benzamide
58		N-((2,6-dimethoxyphenyl)sulfonyl)-3-methoxy-4-((thiazol-2-yloxy)methyl)benzamide
59		N-((2,6-dimethoxyphenyl)sulfonyl)-3-methoxy-4-(thiazol-2-yloxy)benzamide
60		4-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxy-3-methylphenyl)sulfonyl)-3-methoxybenzamide
61		4-((1H-pyrazol-1-yl)methyl)-N-((3-cyclopropyl-2,6-dimethoxyphenyl)sulfonyl)-3-methoxybenzamide
62		4-((1H-pyrazol-1-yl)methyl)-N-((2-cyclopropoxyphenyl)sulfonyl)-3-methoxybenzamide
63		4-((1H-pyrazol-1-yl)methyl)-N-((5-chloro-2,3-dihydrobenzofuran-7-yl)sulfonyl)-3-methoxybenzamide

No.	Structure	Name
64		4-((1H-pyrazol-1-yl)methyl)-N-((2,3-dihydrobenzofuran-5-yl)sulfonyl)-3-methoxybenzamide
65		4-((1H-pyrazol-1-yl)methyl)-N-((3-chloro-4-methoxyphenyl)sulfonyl)-3-methoxybenzamide
66		4-((1H-pyrazol-1-yl)methyl)-N-((3-ethyl-2,6-dimethoxyphenyl)sulfonyl)-3-methoxybenzamide
67		4-((1H-pyrazol-1-yl)methyl)-N-((2-ethoxy-6-methoxyphenyl)sulfonyl)-3-methoxybenzamide
68		4-((1H-pyrazol-1-yl)methyl)-3-methoxy-N-((2-methoxy-6-(2,2,2-trifluoroethoxy)phenyl)sulfonyl)benzamide
69		4-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxyphenyl)sulfonyl)-2-fluoro-3-methoxybenzamide
70		4-((1H-pyrazol-1-yl)methyl)-N-((2,3-dihydrobenzofuran-7-yl)sulfonyl)-3-methoxybenzamide
309		4-((1H-pyrazol-1-yl)methyl)-N-((5-chloro-2,3-dihydrobenzofuran-7-yl)sulfonyl)-3-methoxybenzamide
310		4-((1H-pyrazol-1-yl)methyl)-N-((2,3-dihydrobenzofuran-5-yl)sulfonyl)-3-methoxybenzamide

No.	Structure	Name
311		4-((1H-pyrazol-1-yl)methyl)-N-((3-chloro-4-methoxyphenyl)sulfonyl)-3-methoxybenzamide
312		4-((1H-pyrazol-1-yl)methyl)-N-((6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)-3-methoxybenzamide
314		4-((1H-pyrazol-1-yl)methyl)-3-methoxy-N-((2-methyl-2,3-dihydrobenzofuran-7-yl)sulfonyl)benzamide
315		4-((1H-pyrazol-1-yl)methyl)-N-((2,3-dihydrobenzofuran-7-yl)sulfonyl)-3-methoxybenzamide

.

7. The compound of claim 1, having Formula (II):


(II),

or a pharmaceutically acceptable salt thereof,

wherein

each R^1 is independently C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, C_1-C_6 hydroxyalkyl, C_2-C_6 alkoxyalkyl, halogen, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, -C(O)R^{1a}, -C(O)OR^{1a}, -OC(O)R^{1a}, -C(O)N(R^{1a})(R^{1b}), -N(R^{1a})C(O)(R^{1b}), -OC(O)N(R^{1a})(R^{1b}), -N(R^{1a})C(O)(OR^{1b}), -S(O)R^{1a}, -$S(O)_2R^{1a}$, -$S(O)_2$N(R^{1a})(R^{1b}), -S(O)(NH)R^{1a}, -S(O)(NH)N(R^{1a})(R^{1b}), -N(R^{1a})(R^{1b}), OH, -CN, -NO_2, C_3-C_8 cycloalkyl, (C_1-C_3 alkyl)(C_3-C_8 cycloalkyl), -O-(C_3-C_8 cycloalkyl), heterocycloalkyl, (C_1-C_3 alkyl)(heterocycloalkyl), -O-(heterocycloalkyl), C_6-C_{10} aryl, (C_1-C_3 alkyl)(C_6-

C_{10} aryl), -O-(C_6-C_{10} aryl), heteroaryl, (C_1-C_3 alkyl)(heteroaryl), or –O-(heteroaryl), wherein each alkyl is substituted with 0, 1, 2, 3, 4, 5, or 6 R^{1c}, each alkoxy and alkynyl is substituted with 0, 1, 2, or 3 R^{1d}, and each cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is substituted with 0, 1, 2, or 3 R^{1e};

each R^{1a} and R^{1b} is independently hydrogen or C_1-C_6 alkyl;

each R^{1c} is independently C_1-C_6 alkoxy, halogen, C_1-C_6 haloalkoxy, -$NR^{1c1}R^{1c2}$, OH, or -CN;

each R^{1c1} and R^{1c2} is independently hydrogen or C_1-C_6 alkyl;

each R^{1d} is independently deuterium, C_3-C_8 cycloalkyl, heterocycloalkyl, C_6-C_{10} aryl, or heteroaryl;

each R^{1e} is independently C_1-C_6 alkyl, C_1-C_6 alkoxy, halogen, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, OH, or -CN;

alternatively, two R^1 groups on adjacent carbons together with the atoms to which they are attached combine to form a C_5-C_8 cycloalkyl or a heterocycloalkyl substituted with 0, 1, 2, 3, 4, 5, or 6 halogen, C_1-C_4 alkyl, OH or -CN;

L is –C_1-C_4 alkylene-, –(C_1-C_4 alkylene)-O-, or –O-;

R^2 is a heteroaryl, which is substituted with 0, 1, 2, 3, or 4 R^{2a};

each R^{2a} is independently C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, C_1-C_6 hydroxyalkyl, C_2-C_6 alkoxyalkyl, halogen, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, -$C(O)R^{2b}$, -$C(O)OR^{2b}$, -$OC(O)R^{2b}$, -$C(O)N(R^{2b})(R^{2c})$, -$N(R^{2b})C(O)(R^{2c})$, -$S(O)_2R^{2b}$, -$S(O)_2N(R^{2b})(R^{2c})$, -$N(R^{2b})(R^{2c})$, OH, -CN, or –NO_2;

each R^{2b} and R^{2c} is independently hydrogen or C_1-C_6 alkyl;

Y is CH, CR^3, or N;

each R^3 is independently C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, C_1-C_6 hydroxyalkyl, C_2-C_6 alkoxyalkyl, halogen, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, -$C(O)R^{3a}$, -$C(O)OR^{3a}$, -$OC(O)R^{3a}$, -$C(O)N(R^{3a})(R^{3b})$, -$N(R^{3a})C(O)(R^{3b})$, -$OC(O)N(R^{3a})(R^{3b})$, -$N(R^{3a})C(O)(OR^{3b})$, -$S(O)R^{3a}$, -$S(O)_2R^{3a}$, -$S(O)_2N(R^{3a})(R^{3b})$, -$S(O)(NH)R^{3a}$, -$S(O)(NH)N(R^{3a})(R^{3b})$, -$N(R^{3a})(R^{3b})$, OH, -CN, -$NO_2$, C_3-C_8 cycloalkyl, (C_1-C_3 alkyl)(C_3-C_8 cycloalkyl), -O-(C_3-C_8 cycloalkyl), heterocycloalkyl, (C_1-C_3 alkyl)(heterocycloalkyl), -O-(heterocycloalkyl), C_6-C_{10} aryl, (C_1-C_3 alkyl)(C_6-C_{10} aryl), -O-(C_6-C_{10} aryl), heteroaryl, (C_1-C_3 alkyl)(heteroaryl), or –O-(heteroaryl), wherein each alkyl is substituted with 0, 1, 2, 3, 4, 5, or 6 R^{3c}, each

alkoxy is substituted with 0, 1, 2, or 3 R^{3d}, and each cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is substituted with 0, 1, 2, or 3 R^{3e}; or,

two R^3 on the same carbon atom together represent an oxo group;

each R^{3a} and R^{3b} is independently hydrogen or C_1-C_6 alkyl;

each R^{3c} is independently C_1-C_6 alkoxy, halogen, C_1-C_6 haloalkoxy, -$NR^{3c1}R^{3c2}$, OH, or -CN;

each R^{3c1} and R^{3c2} is independently hydrogen or C_1-C_6 alkyl;

each R^{3d} is independently C_3-C_8 cycloalkyl, heterocycloalkyl, phenyl, or heteroaryl;

each R^{3e} is independently C_1-C_6 alkyl, C_1-C_6 alkoxy, halogen, C_1-C_6 haloalkyl, or C_1-C_6 haloalkoxy;

subscript n is 0, 1, 2, 3, or 4; and

subscript q is 0, 1, 2, 3, or 4;

wherein

each heterocycloalkyl is a 3- to 8-membered ring that includes 1 to 4 heteroatoms each independently N, O or S; and

each heteroaryl is a 5- to 6-membered ring that includes 1 to 4 heteroatoms each independently N, O or S.

8. The compound of claim 7, or a pharmaceutically acceptable salt thereof, wherein

Each R^1 is independently C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 hydroxyalkyl, C_2-C_6 alkoxyalkyl, halogen, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, OH, -CN, C_3-C_8 cycloalkyl, (C_1-C_3 alkyl)(C_3-C_8 cycloalkyl), -O-(C_3-C_8 cycloalkyl), heterocycloalkyl, (C_1-C_3 alkyl)(heterocycloalkyl), -O-(heterocycloalkyl), C_6-C_{10} aryl, or heteroaryl, wherein each alkyl is substituted with 0, 1, 2, or 3 R^{1c}, and each alkoxy and alkynyl is substituted with 0, 1, 2, or 3 R^{1d}; or

alternatively, two R^1 on adjacent carbons together with the atoms to which they are attached combine to form a C_5-C_8 cycloalkyl or a heterocycloalkyl.








9. The compound of claim 7 or 8, or a pharmaceutically acceptable salt thereof, wherein











L is –CH_2-, –CH_2O-, or –O-.










10. The compound of any one of claims 7 to 9, or a pharmaceutically acceptable salt thereof, wherein











each R^3 is independently C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 hydroxyalkyl, C_2-C_6 alkoxyalkyl, halogen, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, -$C(O)R^{3a}$, -$C(O)OR^{3a}$, -$OC(O)R^{3a}$, -$C(O)N(R^{3a})(R^{3b})$, -$N(R^{3a})C(O)(R^{3b})$, -$S(O)_2R^{3a}$, -$S(O)_2N(R^{3a})(R^{3b})$, OH, -CN, C_3-C_8 cycloalkyl, or heterocycloalkyl.











11. The compound of any one of claims 7 to 10, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the following compounds:










No.	Structure	Name
201		5-((1H-pyrazol-1-yl)methyl)-N-((5-(tert-butyl)-2-methoxyphenyl)sulfonyl)picolinamide
202		6-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxyphenyl)sulfonyl)-5-methoxynicotinamide
203		5-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxyphenyl)sulfonyl)-6-methoxypicolinamide
204		5-((1H-pyrazol-1-yl)methyl)-N-((5-ethyl-2-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
205		5-((1H-pyrazol-1-yl)methyl)-N-((5-(tert-butyl)-2-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
206		5-((1H-pyrazol-1-yl)methyl)-N-((5-cyclopropyl-2-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
207		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-((2-methoxy-5-(trifluoromethyl)phenyl)sulfonyl)picolinamide











No.	Structure	Name
208		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-((2-methoxyphenyl)sulfonyl)picolinamide
209		5-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxyphenyl)sulfonyl)-6-methylpicolinamide
210		5-((1H-pyrazol-1-yl)methyl)-N-((5-ethyl-2-methoxyphenyl)sulfonyl)-4-methoxypicolinamide
211		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-((6-methoxy-2,3-dihydrobenzofuran-7-yl)sulfonyl)picolinamide
212		5-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxyphenyl)sulfonyl)-4-methoxypicolinamide
213		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-((6-methoxy-2,3-dihydro-1H-inden-5-yl)sulfonyl)picolinamide
214		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-((2-methoxy-5-methylphenyl)sulfonyl)picolinamide
215		5-((1H-pyrazol-1-yl)methyl)-6-(difluoromethoxy)-N-((2,6-dimethoxyphenyl)sulfonyl)picolinamide
216		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-((5-methoxy-2,3-dihydro-1H-inden-4-yl)sulfonyl)picolinamide
217		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-((2-methoxy-5,6,7,8-tetrahydronaphthalen-1-yl)sulfonyl)picolinamide











No.	Structure	Name
218		5-((1H-pyrazol-1-yl)methyl)-N-((2-ethoxy-6-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
219		5-((1H-pyrazol-1-yl)methyl)-N-((2-cyclobutoxy-6-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
220		5-((1H-pyrazol-1-yl)methyl)-N-((2-(difluoromethoxy)-6-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
221		5-((1H-pyrazol-1-yl)methyl)-N-((2-isopropoxy-6-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
222		5-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxy-3-methylphenyl)sulfonyl)-6-methoxypicolinamide
223		5-((1H-pyrazol-1-yl)methyl)-N-((3-cyclopropyl-2,6-dimethoxyphenyl)sulfonyl)-6-methoxypicolinamide
224		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-((2,4,6-trimethoxyphenyl)sulfonyl)picolinamide
225		5-((1H-pyrazol-1-yl)methyl)-N-((3-ethyl-2,6-dimethoxyphenyl)sulfonyl)-6-methoxypicolinamide
226		5-((1H-pyrazol-1-yl)methyl)-N-((2,4-dimethoxyphenyl)sulfonyl)-6-methoxypicolinamide











No.	Structure	Name
227		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-((2-methoxy-6-(2,2,2-trifluoroethoxy)phenyl)sulfonyl)picolinamide
228		5-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxyphenyl)sulfonyl)-6-(trifluoromethoxy)picolinamide
229		5-((1H-pyrazol-1-yl)methyl)-6-cyclopropyl-N-((2,6-dimethoxyphenyl)sulfonyl)picolinamide
230		5-((1H-pyrazol-1-yl)methyl)-N-((5-(2-hydroxypropan-2-yl)-2-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
231		5-((1H-pyrazol-1-yl)methyl)-6-(difluoromethyl)-N-((2,6-dimethoxyphenyl)sulfonyl)picolinamide
233		5-((1H-pyrazol-1-yl)methyl)-N-((2,3-dihydro-1H-inden-4-yl)sulfonyl)-6-methoxypicolinamide
234		5-((1H-pyrazol-1-yl)methyl)-N-((2,3-dihydro-1H-inden-5-yl)sulfonyl)-6-methoxypicolinamide
235		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-((2-methoxy-6-(trifluoromethoxy)phenyl)sulfonyl)picolinamide
236		5-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxyphenyl)sulfonyl)-6-(trifluoromethyl)picolinamide
237		5-((1H-pyrazol-1-yl)methyl)-N-((3-(2-hydroxypropan-2-yl)phenyl)sulfonyl)-6-methoxypicolinamide











No.	Structure	Name
238		5-((1H-pyrazol-1-yl)methyl)-N-((5-chloro-2,4-dimethoxyphenyl)sulfonyl)-6-methoxypicolinamide
239		5-((1H-pyrazol-1-yl)methyl)-N-((5-(2-hydroxybutan-2-yl)-2-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
240		5-((1H-pyrazol-1-yl)methyl)-N-((5-(1-cyclopropyl-1-hydroxyethyl)-2-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
241		5-((1H-pyrazol-1-yl)methyl)-N-((3-chloro-2,6-dimethoxyphenyl)sulfonyl)-6-methoxypicolinamide
242		5-((1H-pyrazol-1-yl)methyl)-N-((5-bromo-2,4-dimethoxyphenyl)sulfonyl)-6-methoxypicolinamide
244		5-((1H-pyrazol-1-yl)methyl)-N-((5-fluoro-2,4-dimethoxyphenyl)sulfonyl)-6-methoxypicolinamide
245		5-((1H-pyrazol-1-yl)methyl)-N-((2-(cyclopropylmethoxy)-6-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
246		5-((1H-pyrazol-1-yl)methyl)-N-((2,3-dihydrobenzofuran-7-yl)sulfonyl)-6-methoxypicolinamide
247		5-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxyphenyl)sulfonyl)-6-ethylpicolinamide
248		5-((1H-pyrazol-1-yl)methyl)-N-((2-cyclopropoxy-6-methoxyphenyl)sulfonyl)-6-methoxypicolinamide










No.	Structure	Name
249		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-((7-methoxychroman-8-yl)sulfonyl)picolinamide
250		5-((1H-pyrazol-1-yl)methyl)-N-((3-ethyl-2,4,6-trimethoxyphenyl)sulfonyl)-6-methoxypicolinamide
251		5-((1H-pyrazol-1-yl)methyl)-N-((6-ethoxy-3-ethyl-2-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
252		5-((1H-pyrazol-1-yl)methyl)-N-((3-ethyl-2-methoxy-6-(2,2,2-trifluoroethoxy)phenyl)sulfonyl)-6-methoxypicolinamide
253		5-((1H-pyrazol-1-yl)methyl)-N-((4,6-dimethoxy-2,3-dihydrobenzofuran-7-yl)sulfonyl)-6-methoxypicolinamide
254		5-((1H-pyrazol-1-yl)methyl)-N-((3,3-difluoro-6-methoxy-2,3-dihydrobenzofuran-7-yl)sulfonyl)-6-methoxypicolinamide
255		5-((1H-pyrazol-1-yl)methyl)-N-((5-(1-hydroxycyclopropyl)-2-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
256		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-((2-methoxy-5-(2-methoxypropan-2-yl)phenyl)sulfonyl)picolinamide
257		5-((1H-pyrazol-1-yl)methyl)-N-((5-(tert-butyl)-2,3-dihydrobenzofuran-7-yl)sulfonyl)-6-methoxypicolinamide











No.	Structure	Name
258		5-((1H-pyrazol-1-yl)methyl)-N-((5-(1-hydroxy-2-methylpropan-2-yl)-2-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
259		5-((1H-pyrazol-1-yl)methyl)-N-((5-(1-hydroxycyclobutyl)-2-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
264		5-((1H-pyrazol-1-yl)methyl)-N-((4-(tert-butyl)-2-methoxyphenyl)sulfonyl)-4-methoxypyrimidine-2-carboxamide
265		5-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxyphenyl)sulfonyl)-6-ethylpicolinamide
266		5-((1H-pyrazol-1-yl)methyl)-N-((5-(1-hydroxy-2-methylpropan-2-yl)-2-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
267		6-((1H-pyrazol-1-yl)methyl)-N-((5-(tert-butyl)-2-methoxyphenyl)sulfonyl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide
268		5-((1H-pyrazol-1-yl)methyl)-N-((3-ethyl-2,4,6-trimethoxyphenyl)sulfonyl)-6-methoxypicolinamide
269		5-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxy-4-(pyridin-3-ylethynyl)phenyl)sulfonyl)-6-methoxypicolinamide
270		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-((2,4,6-tris(methoxy-d3)phenyl)sulfonyl)picolinamide
271		5-((1H-pyrazol-1-yl)methyl)-N-((5-ethyl-2-methoxyphenyl)sulfonyl)-4-methoxypyrimidine-2-carboxamide











No.	Structure	Name
272		5-((1H-pyrazol-1-yl)methyl)-4-methoxy-N-((2,4,6-trimethoxyphenyl)sulfonyl)pyrimidine-2-carboxamide
273		5-((1H-pyrazol-1-yl)methyl)-N-((5-cyclopropyl-2-methoxyphenyl)sulfonyl)-4-methoxypyrimidine-2-carboxamide
274		5-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxyphenyl)sulfonyl)-4-methoxypyrimidine-2-carboxamide
275		5-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxy-4-methylphenyl)sulfonyl)-6-methoxypicolinamide
276		5-((1H-pyrazol-1-yl)methyl)-N-((5-bromo-2,4-dimethoxyphenyl)sulfonyl)-6-methoxypicolinamide
277		5-((1H-pyrazol-1-yl)methyl)-N-((5-fluoro-2,4-dimethoxyphenyl)sulfonyl)-6-methoxypicolinamide
278		5-((1H-pyrazol-1-yl)methyl)-N-((5-(tert-butyl)-2-methoxyphenyl)sulfonyl)-1-methyl-6-oxo-1,6-dihydropyridine-2-carboxamide
279		5-((1H-pyrazol-1-yl)methyl)-N-((2-cyclopropoxy-6-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
280		5-((1H-pyrazol-1-yl)methyl)-N-((5-(tert-butyl)-2,3-dihydrobenzofuran-7-yl)sulfonyl)-6-methoxypicolinamide
281		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-((5-methoxybenzo[d][1,3]dioxol-4-yl)sulfonyl)picolinamide










No.	Structure	Name
282		5-((1H-pyrazol-1-yl)methyl)-N-((4-fluoro-2,6-dimethoxyphenyl)sulfonyl)-6-methoxypicolinamide
283		5-((1H-pyrazol-1-yl)methyl)-N-((4-chloro-2,6-dimethoxyphenyl)sulfonyl)-6-methoxypicolinamide
284		5-((1H-pyrazol-1-yl)methyl)-N-((6-ethoxy-3-ethyl-2-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
285		5-((1H-pyrazol-1-yl)methyl)-N-((4-bromo-2,6-dimethoxyphenyl)sulfonyl)-6-methoxypicolinamide
286		5-((1H-pyrazol-1-yl)methyl)-N-((2,4-dimethoxy-6-methylphenyl)sulfonyl)-6-methoxypicolinamide
287		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-((5-(trifluoromethyl)-2,3-dihydrobenzofuran-7-yl)sulfonyl)picolinamide
288		5-((1H-pyrazol-1-yl)methyl)-N-((2-fluoro-4,6-dimethoxyphenyl)sulfonyl)-6-methoxypicolinamide
289		5-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxyphenyl)sulfonyl)-6-ethoxypicolinamide
No.	Structure	Name
201		5-((1H-pyrazol-1-yl)methyl)-N-((5-(tert-butyl)-2-methoxyphenyl)sulfonyl)picolinamide
202		6-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxyphenyl)sulfonyl)-5-methoxynicotinamide











No.	Structure	Name
203		5-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxyphenyl)sulfonyl)-6-methoxypicolinamide
204		5-((1H-pyrazol-1-yl)methyl)-N-((5-ethyl-2-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
205		5-((1H-pyrazol-1-yl)methyl)-N-((5-(tert-butyl)-2-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
206		5-((1H-pyrazol-1-yl)methyl)-N-((5-cyclopropyl-2-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
207		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-((2-methoxy-5-(trifluoromethyl)phenyl)sulfonyl)picolinamide
208		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-((2-methoxyphenyl)sulfonyl)picolinamide
209		5-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxyphenyl)sulfonyl)-6-methylpicolinamide
210		5-((1H-pyrazol-1-yl)methyl)-N-((5-ethyl-2-methoxyphenyl)sulfonyl)-4-methoxypicolinamide
211		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-((6-methoxy-2,3-dihydrobenzofuran-7-yl)sulfonyl)picolinamide
212		5-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxyphenyl)sulfonyl)-4-methoxypicolinamide












No.	Structure	Name
213		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-((6-methoxy-2,3-dihydro-1H-inden-5-yl)sulfonyl)picolinamide
214		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-((2-methoxy-5-methylphenyl)sulfonyl)picolinamide
215		5-((1H-pyrazol-1-yl)methyl)-6-(difluoromethoxy)-N-((2,6-dimethoxyphenyl)sulfonyl)picolinamide
216		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-((5-methoxy-2,3-dihydro-1H-inden-4-yl)sulfonyl)picolinamide
217		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-((2-methoxy-5,6,7,8-tetrahydronaphthalen-1-yl)sulfonyl)picolinamide
218		5-((1H-pyrazol-1-yl)methyl)-N-((2-ethoxy-6-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
219		5-((1H-pyrazol-1-yl)methyl)-N-((2-cyclobutoxy-6-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
220		5-((1H-pyrazol-1-yl)methyl)-N-((2-(difluoromethoxy)-6-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
221		5-((1H-pyrazol-1-yl)methyl)-N-((2-isopropoxy-6-methoxyphenyl)sulfonyl)-6-methoxypicolinamide










No.	Structure	Name
222		5-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxy-3-methylphenyl)sulfonyl)-6-methoxypicolinamide
223		5-((1H-pyrazol-1-yl)methyl)-N-((3-cyclopropyl-2,6-dimethoxyphenyl)sulfonyl)-6-methoxypicolinamide
224		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-((2,4,6-trimethoxyphenyl)sulfonyl)picolinamide
225		5-((1H-pyrazol-1-yl)methyl)-N-((3-ethyl-2,6-dimethoxyphenyl)sulfonyl)-6-methoxypicolinamide
226		5-((1H-pyrazol-1-yl)methyl)-N-((2,4-dimethoxyphenyl)sulfonyl)-6-methoxypicolinamide
227		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-((2-methoxy-6-(2,2,2-trifluoroethoxy)phenyl)sulfonyl)picolinamide
228		5-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxyphenyl)sulfonyl)-6-(trifluoromethoxy)picolinamide
229		5-((1H-pyrazol-1-yl)methyl)-6-cyclopropyl-N-((2,6-dimethoxyphenyl)sulfonyl)picolinamide
230		5-((1H-pyrazol-1-yl)methyl)-N-((5-(2-hydroxypropan-2-yl)-2-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
231		5-((1H-pyrazol-1-yl)methyl)-6-(difluoromethyl)-N-((2,6-dimethoxyphenyl)sulfonyl)picolinamide




No.	Structure	Name
233		5-((1H-pyrazol-1-yl)methyl)-N-((2,3-dihydro-1H-inden-4-yl)sulfonyl)-6-methoxypicolinamide
234		5-((1H-pyrazol-1-yl)methyl)-N-((2,3-dihydro-1H-inden-5-yl)sulfonyl)-6-methoxypicolinamide
235		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-((2-methoxy-6-(trifluoromethoxy)phenyl)sulfonyl)picolinamide
236		5-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxyphenyl)sulfonyl)-6-(trifluoromethyl)picolinamide
237		5-((1H-pyrazol-1-yl)methyl)-N-((3-(2-hydroxypropan-2-yl)phenyl)sulfonyl)-6-methoxypicolinamide
238		5-((1H-pyrazol-1-yl)methyl)-N-((5-chloro-2,4-dimethoxyphenyl)sulfonyl)-6-methoxypicolinamide
239		5-((1H-pyrazol-1-yl)methyl)-N-((5-(2-hydroxybutan-2-yl)-2-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
240		5-((1H-pyrazol-1-yl)methyl)-N-((5-(1-cyclopropyl-1-hydroxyethyl)-2-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
241		5-((1H-pyrazol-1-yl)methyl)-N-((3-chloro-2,6-dimethoxyphenyl)sulfonyl)-6-methoxypicolinamide
242		5-((1H-pyrazol-1-yl)methyl)-N-((5-bromo-2,4-dimethoxyphenyl)sulfonyl)-6-methoxypicolinamide

No.	Structure	Name
244		5-((1H-pyrazol-1-yl)methyl)-N-((5-fluoro-2,4-dimethoxyphenyl)sulfonyl)-6-methoxypicolinamide
245		5-((1H-pyrazol-1-yl)methyl)-N-((2-(cyclopropylmethoxy)-6-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
246		5-((1H-pyrazol-1-yl)methyl)-N-((2,3-dihydrobenzofuran-7-yl)sulfonyl)-6-methoxypicolinamide
247		5-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxyphenyl)sulfonyl)-6-ethylpicolinamide
248		5-((1H-pyrazol-1-yl)methyl)-N-((2-cyclopropoxy-6-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
249		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-((7-methoxychroman-8-yl)sulfonyl)picolinamide
250		5-((1H-pyrazol-1-yl)methyl)-N-((3-ethyl-2,4,6-trimethoxyphenyl)sulfonyl)-6-methoxypicolinamide
251		5-((1H-pyrazol-1-yl)methyl)-N-((6-ethoxy-3-ethyl-2-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
252		5-((1H-pyrazol-1-yl)methyl)-N-((3-ethyl-2-methoxy-6-(2,2,2-trifluoroethoxy)phenyl)sulfonyl)-6-methoxypicolinamide

No.	Structure	Name
253		5-((1H-pyrazol-1-yl)methyl)-N-((4,6-dimethoxy-2,3-dihydrobenzofuran-7-yl)sulfonyl)-6-methoxypicolinamide
254		5-((1H-pyrazol-1-yl)methyl)-N-((3,3-difluoro-6-methoxy-2,3-dihydrobenzofuran-7-yl)sulfonyl)-6-methoxypicolinamide
255		5-((1H-pyrazol-1-yl)methyl)-N-((5-(1-hydroxycyclopropyl)-2-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
256		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-((2-methoxy-5-(2-methoxypropan-2-yl)phenyl)sulfonyl)picolinamide
257		5-((1H-pyrazol-1-yl)methyl)-N-((5-(tert-butyl)-2,3-dihydrobenzofuran-7-yl)sulfonyl)-6-methoxypicolinamide
258		5-((1H-pyrazol-1-yl)methyl)-N-((5-(1-hydroxy-2-methylpropan-2-yl)-2-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
259		5-((1H-pyrazol-1-yl)methyl)-N-((5-(1-hydroxycyclobutyl)-2-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
264		5-((1H-pyrazol-1-yl)methyl)-N-((4-(tert-butyl)-2-methoxyphenyl)sulfonyl)-4-methoxypyrimidine-2-carboxamide
265		5-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxyphenyl)sulfonyl)-6-ethylpicolinamide
266		5-((1H-pyrazol-1-yl)methyl)-N-((5-(1-hydroxy-2-methylpropan-2-yl)-2-methoxyphenyl)sulfonyl)-6-methoxypicolinamide


No.	Structure	Name
267		6-((1H-pyrazol-1-yl)methyl)-N-((5-(tert-butyl)-2-methoxyphenyl)sulfonyl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide
268		5-((1H-pyrazol-1-yl)methyl)-N-((3-ethyl-2,4,6-trimethoxyphenyl)sulfonyl)-6-methoxypicolinamide
269		5-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxy-4-(pyridin-3-ylethynyl)phenyl)sulfonyl)-6-methoxypicolinamide
270		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-((2,4,6-tris(methoxy-d3)phenyl)sulfonyl)picolinamide
271		5-((1H-pyrazol-1-yl)methyl)-N-((5-ethyl-2-methoxyphenyl)sulfonyl)-4-methoxypyrimidine-2-carboxamide
272		5-((1H-pyrazol-1-yl)methyl)-4-methoxy-N-((2,4,6-trimethoxyphenyl)sulfonyl)pyrimidine-2-carboxamide
273		5-((1H-pyrazol-1-yl)methyl)-N-((5-cyclopropyl-2-methoxyphenyl)sulfonyl)-4-methoxypyrimidine-2-carboxamide
274		5-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxyphenyl)sulfonyl)-4-methoxypyrimidine-2-carboxamide
275		5-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxy-4-methylphenyl)sulfonyl)-6-methoxypicolinamide
276		5-((1H-pyrazol-1-yl)methyl)-N-((5-bromo-2,4-dimethoxyphenyl)sulfonyl)-6-methoxypicolinamide
277		5-((1H-pyrazol-1-yl)methyl)-N-((5-fluoro-2,4-dimethoxyphenyl)sulfonyl)-6-methoxypicolinamide

No.	Structure	Name
278		5-((1H-pyrazol-1-yl)methyl)-N-((5-(tert-butyl)-2-methoxyphenyl)sulfonyl)-1-methyl-6-oxo-1,6-dihydropyridine-2-carboxamide
279		5-((1H-pyrazol-1-yl)methyl)-N-((2-cyclopropoxy-6-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
280		5-((1H-pyrazol-1-yl)methyl)-N-((5-(tert-butyl)-2,3-dihydrobenzofuran-7-yl)sulfonyl)-6-methoxypicolinamide
281		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-((5-methoxybenzo[d][1,3]dioxol-4-yl)sulfonyl)picolinamide
282		5-((1H-pyrazol-1-yl)methyl)-N-((4-fluoro-2,6-dimethoxyphenyl)sulfonyl)-6-methoxypicolinamide
283		5-((1H-pyrazol-1-yl)methyl)-N-((4-chloro-2,6-dimethoxyphenyl)sulfonyl)-6-methoxypicolinamide
284		5-((1H-pyrazol-1-yl)methyl)-N-((6-ethoxy-3-ethyl-2-methoxyphenyl)sulfonyl)-6-methoxypicolinamide
285		5-((1H-pyrazol-1-yl)methyl)-N-((4-bromo-2,6-dimethoxyphenyl)sulfonyl)-6-methoxypicolinamide
286		5-((1H-pyrazol-1-yl)methyl)-N-((2,4-dimethoxy-6-methylphenyl)sulfonyl)-6-methoxypicolinamide

No.	Structure	Name
287		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-((5-(trifluoromethyl)-2,3-dihydrobenzofuran-7-yl)sulfonyl)picolinamide
288		5-((1H-pyrazol-1-yl)methyl)-N-((2-fluoro-4,6-dimethoxyphenyl)sulfonyl)-6-methoxypicolinamide
289		5-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxyphenyl)sulfonyl)-6-ethoxypicolinamide


.

12. The compound of any one of claims 7 to 11, or a pharmaceutically acceptable salt thereof, wherein the compound has the structure:




.

13. The compound of any one of claims 7 to 11, having the structure:




.

14. The compound of any one of claims 7 to 11, or a pharmaceutically acceptable salt thereof, wherein the compound has the structure:




.

15. The compound of any one of claims 7 to 11, having the structure:




.

16. The compound of any one of claims 7 to 11, or a pharmaceutically acceptable salt thereof, wherein the compound has the structure:




.

17. The compound of any one of claims 7 to 11, having the structure:



.

18. The compound of claim 1, having Formula (III):



(III),

or a pharmaceutically acceptable salt thereof,

wherein

each R^1 is independently C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, C_1-C_6 hydroxyalkyl, C_2-C_6 alkoxyalkyl, halogen, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, $-C(O)R^{1a}$, $-C(O)OR^{1a}$, $-OC(O)R^{1a}$, $-C(O)N(R^{1a})(R^{1b})$, $-N(R^{1a})C(O)(R^{1b})$, $-OC(O)N(R^{1a})(R^{1b})$, $-N(R^{1a})C(O)(OR^{1b})$, $-S(O)R^{1a}$, $-S(O)_2R^{1a}$, $-S(O)_2N(R^{1a})(R^{1b})$, $-S(O)(NH)R^{1a}$, $-S(O)(NH)N(R^{1a})(R^{1b})$,

-N(R^{1a})(R^{1b}), OH, -CN, -NO_2, C_3-C_8 cycloalkyl, (C_1-C_3 alkyl)(C_3-C_8 cycloalkyl), -O-(C_3-C_8 cycloalkyl), heterocycloalkyl, (C_1-C_3 alkyl)(heterocycloalkyl), -O-(heterocycloalkyl), C_6-C_{10} aryl, (C_1-C_3 alkyl)(C_6-C_{10} aryl), -O-(C_6-C_{10} aryl), heteroaryl, (C_1-C_3 alkyl)(heteroaryl), or –O-(heteroaryl), wherein each alkyl is substituted with 0, 1, 2, 3, 4, 5, or 6 R^{1c}, each alkoxy and alkynyl is substituted with 0, 1, 2, or 3 R^{1d}, and each cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is substituted with 0, 1, 2, or 3 R^{1e};

each R^{1a} and R^{1b} is independently hydrogen or C_1-C_6 alkyl;

each R^{1c} is independently C_1-C_6 alkoxy, halogen, C_1-C_6 haloalkoxy, -$NR^{1c1}R^{1c2}$, OH, or -CN;

each R^{1c1} and R^{1c2} is independently hydrogen or C_1-C_6 alkyl;

each R^{1d} is independently deuterium, C_3-C_8 cycloalkyl, heterocycloalkyl, C_6-C_{10} aryl, or heteroaryl;

each R^{1e} is independently C_1-C_6 alkyl, C_1-C_6 alkoxy, halogen, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, OH, or -CN;

alternatively, two R^1 groups on adjacent carbons together with the atoms to which they are attached combine to form a C_5-C_8 cycloalkyl or a heterocycloalkyl substituted with 0, 1, 2, 3, 4, 5, or 6 halogen, C_1-C_4 alkyl, OH or -CN;

L is –C_1-C_4 alkylene-, –(C_1-C_4 alkylene)-O-, or –O-;

R^2 is a heteroaryl, which is substituted with 0, 1, 2, 3, or 4 R^{2a};

each R^{2a} is independently C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, C_1-C_6 hydroxyalkyl, C_2-C_6 alkoxyalkyl, halogen, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, -C(O)R^{2b}, -C(O)OR^{2b}, -OC(O)R^{2b}, -C(O)N(R^{2b})(R^{2c}), -N(R^{2b})C(O)(R^{2c}), -S(O)$_2$$R^{2b}$, -S(O)$_2$N($R^{2b}$)($R^{2c}$), -N($R^{2b}$)($R^{2c}$), -OH, -CN, or –$NO_2$;

each R^{2b} and R^{2c} is independently hydrogen or C_1-C_6 alkyl;

each R^3 is independently C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, C_1-C_6 hydroxyalkyl, C_2-C_6 alkoxyalkyl, halogen, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, -C(O)R^{3a}, -C(O)OR^{3a}, -OC(O)R^{3a}, -C(O)N(R^{3a})(R^{3b}), -N(R^{3a})C(O)(R^{3b}), -OC(O)N(R^{3a})(R^{3b}), -N(R^{3a})C(O)(OR^{3b}), -S(O)R^{3a}, -S(O)$_2$$R^{3a}$, -S(O)$_2$N($R^{3a}$)($R^{3b}$), -S(O)(NH)$R^{3a}$, -S(O)(NH)N($R^{3a}$)($R^{3b}$), -N($R^{3a}$)($R^{3b}$), OH, -CN, -$NO_2$, C_3-C_8 cycloalkyl, (C_1-C_3 alkyl)(C_3-C_8 cycloalkyl), -O-(C_3-C_8 cycloalkyl), heterocycloalkyl, (C_1-C_3 alkyl)(heterocycloalkyl), -O-(heterocycloalkyl), C_6-C_{10} aryl, (C_1-C_3 alkyl)(C_6-

C_{10} aryl), -O-(C_6-C_{10} aryl), heteroaryl, (C_1-C_3 alkyl)(heteroaryl), or –O-(heteroaryl), wherein each alkyl is substituted with 0, 1, 2, 3, 4, 5, or 6 R^{3c}, each alkoxy is substituted with 0, 1, 2, or 3 R^{3d}, and each cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is substituted with 0, 1, 2, or 3 R^{3e}; or,

two R^3 on the same carbon atom together represent an oxo group;

each R^{3a} and R^{3b} is independently hydrogen or C_1-C_6 alkyl;

each R^{3c} is independently C_1-C_6 alkoxy, halogen, C_1-C_6 haloalkoxy, -$NR^{3c1}R^{3c2}$, OH, or -CN;

each R^{3c1} and R^{3c2} is independently hydrogen or C_1-C_6 alkyl;

each R^{3d} is independently C_3-C_8 cycloalkyl, heterocycloalkyl, phenyl, or heteroaryl;

each R^{3e} is independently C_1-C_6 alkyl, C_1-C_6 alkoxy, halogen, C_1-C_6 haloalkyl, or C_1-C_6 haloalkoxy;

R^4 is hydrogen or C_1-C_6 alkyl;

subscript n is 0, 1, 2, 3, or 4; and




subscript q is 0, 1, 2, 3, or 4;












wherein







each heterocycloalkyl is a 3- to 8-membered ring that includes 1 to 4 heteroatoms each independently N, O or S; and

each heteroaryl is a 5- to 6-membered ring that includes 1 to 4 heteroatoms each independently N, O or S.

19. The compound of claim 18, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the following compounds:


No.	Structure	Name
71		4-((1H-pyrazol-1-yl)methyl)-N-(2,6-dimethoxyphenylsulfonimidoyl)-3-methoxybenzamide
72		4-((1H-pyrazol-1-yl)methyl)-3-methoxy-N-(2-methoxyphenylsulfonimidoyl)benzamide
73		4-((1H-pyrazol-1-yl)methyl)-3-methoxy-N-(2-methoxy-6-(2,2,2-trifluoroethoxy)phenylsulfonimidoyl)benzamide

No.	Structure	Name
74		4-((1H-pyrazol-1-yl)methyl)-N-(2-cyclobutoxy-6-methoxyphenylsulfonimidoyl)-3-methoxybenzamide
75		4-((1H-pyrazol-1-yl)methyl)-N-(2,4-dimethoxyphenylsulfonimidoyl)-3-methoxybenzamide
76		4-((1H-pyrazol-1-yl)methyl)-3-methoxy-N-(2,4,6-trimethoxyphenylsulfonimidoyl)benzamide
291a		(R)-4-((1H-pyrazol-1-yl)methyl)-N-(5-(1-hydroxy-2-methylpropan-2-yl)-2-methoxyphenylsulfonimidoyl)-3-methoxybenzamide
291b		(S)-4-((1H-pyrazol-1-yl)methyl)-N-(5-(1-hydroxy-2-methylpropan-2-yl)-2-methoxyphenylsulfonimidoyl)-3-methoxybenzamide
292		4-((1H-pyrazol-1-yl)methyl)-N-((2,6-dimethoxyphenyl)(methylamino)(oxo)-l6-sulfaneylidene)-3-methoxybenzamide
295a		(R)-4-((1H-pyrazol-1-yl)methyl)-N-(2,6-dimethoxyphenylsulfonimidoyl)-3-methoxybenzamide
295b		(S)-4-((1H-pyrazol-1-yl)methyl)-N-(2,6-dimethoxyphenylsulfonimidoyl)-3-methoxybenzamide
299		4-((1H-pyrazol-1-yl)methyl)-3-methoxy-N-(2,4,6-trimethoxyphenylsulfonimidoyl)benzamide
299a		(R)-4-((1H-pyrazol-1-yl)methyl)-3-methoxy-N-(2,4,6-trimethoxyphenylsulfonimidoyl)benzamide
299b		(S)-4-((1H-pyrazol-1-yl)methyl)-3-methoxy-N-(2,4,6-trimethoxyphenylsulfonimidoyl)benzamide

No.	Structure	Name
300a		(R)-4-((1H-pyrazol-1-yl)methyl)-N-(2,6-dimethoxyphenylsulfonimidoyl)-3-(trifluoromethoxy)benzamide
300b		(S)-4-((1H-pyrazol-1-yl)methyl)-N-(2,6-dimethoxyphenylsulfonimidoyl)-3-(trifluoromethoxy)benzamide
302a		(R)-4-((1H-pyrazol-1-yl)methyl)-N-(3-chloro-2,6-dimethoxyphenylsulfonimidoyl)-3-methoxybenzamide
302b		(S)-4-((1H-pyrazol-1-yl)methyl)-N-(3-chloro-2,6-dimethoxyphenylsulfonimidoyl)-3-methoxybenzamide
304a		(R)-4-((1H-pyrazol-1-yl)methyl)-N-(2,6-dimethoxy-3-methylphenylsulfonimidoyl)-3-methoxybenzamide
304b		(S)-4-((1H-pyrazol-1-yl)methyl)-N-(2,6-dimethoxy-3-methylphenylsulfonimidoyl)-3-methoxybenzamide

.

20. The compound of claim 1, having Formula (IV):


(IV),

or a pharmaceutically acceptable salt thereof,

wherein

each R^1 is independently C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, C_1-C_6 hydroxyalkyl, C_2-C_6 alkoxyalkyl, halogen, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, -C(O)R^{1a}, -C(O)OR^{1a}, -OC(O)R^{1a}, -C(O)N(R^{1a})(R^{1b}), -N(R^{1a})C(O)(R^{1b}), -OC(O)N(R^{1a})(R^{1b}), -N(R^{1a})C(O)(OR^{1b}), -S(O)R^{1a}, -S(O)$_2$$R^{1a}$, -S(O)$_2$N($R^{1a}$)($R^{1b}$), -S(O)(NH)$R^{1a}$, -S(O)(NH)N($R^{1a}$)($R^{1b}$), -N($R^{1a}$)($R^{1b}$), OH, -CN, -$NO_2$, C_3-C_8 cycloalkyl, (C_1-C_3 alkyl)(C_3-C_8 cycloalkyl), -O-(C_3-C_8 cycloalkyl), heterocycloalkyl, (C_1-C_3

alkyl)(heterocycloalkyl), -O-(heterocycloalkyl), C_6-C_{10} aryl, (C_1-C_3 alkyl)(C_6-C_{10} aryl), -O-(C_6-C_{10} aryl), heteroaryl, (C_1-C_3 alkyl)(heteroaryl), or –O-(heteroaryl), wherein each alkyl is substituted with 0, 1, 2, 3, 4, 5, or 6 R^{1c}, each alkoxy and alkynyl is substituted with 0, 1, 2, or 3 R^{1d}, and each cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is substituted with 0, 1, 2, or 3 R^{1e};

each R^{1a} and R^{1b} is independently hydrogen or C_1-C_6 alkyl;

each R^{1c} is independently C_1-C_6 alkoxy, halogen, C_1-C_6 haloalkoxy, -$NR^{1c1}R^{1c2}$, -OH, or -CN;

each R^{1c1} and R^{1c2} is independently hydrogen or C_1-C_6 alkyl;

each R^{1d} is independently deuterium, C_3-C_8 cycloalkyl, heterocycloalkyl, C_6-C_{10} aryl, or heteroaryl;

each R^{1e} is independently C_1-C_6 alkyl, C_1-C_6 alkoxy, halogen, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, -OH, or -CN;

alternatively, two R^1 groups on adjacent carbons together with the atoms to which they are attached combine to form a C_5-C_8 cycloalkyl or a heterocycloalkyl substituted with 0, 1, 2, 3, 4, 5, or 6 halogen, C_1-C_4 alkyl, OH or -CN;

L is –C_1-C_4 alkylene-, –(C_1-C_4 alkylene)-O-, or –O-;

R^2 is a heteroaryl, which is substituted with 0, 1, 2, 3, or 4 R^{2a};

each R^{2a} is independently C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, C_1-C_6 hydroxyalkyl, C_2-C_6 alkoxyalkyl, halogen, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, -$C(O)R^{2b}$, -$C(O)OR^{2b}$, -$OC(O)R^{2b}$, -$C(O)N(R^{2b})(R^{2c})$, -$N(R^{2b})C(O)(R^{2c})$, -$S(O)_2R^{2b}$, -$S(O)_2N(R^{2b})(R^{2c})$, -$N(R^{2b})(R^{2c})$, OH, -CN, or –NO_2;

each R^{2b} and R^{2c} is independently hydrogen or C_1-C_6 alkyl;

Y is CH, CR^3, or N;

each R^3 is independently C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, C_1-C_6 hydroxyalkyl, C_2-C_6 alkoxyalkyl, halogen, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, -$C(O)R^{3a}$, -$C(O)OR^{3a}$, -$OC(O)R^{3a}$, -$C(O)N(R^{3a})(R^{3b})$, -$N(R^{3a})C(O)(R^{3b})$, -$OC(O)N(R^{3a})(R^{3b})$, -$N(R^{3a})C(O)(OR^{3b})$, -$S(O)R^{3a}$, -$S(O)_2R^{3a}$, -$S(O)_2N(R^{3a})(R^{3b})$, -$S(O)(NH)R^{3a}$, -$S(O)(NH)N(R^{3a})(R^{3b})$, -$N(R^{3a})(R^{3b})$, OH, -CN, -$NO_2$, C_3-C_8 cycloalkyl, (C_1-C_3 alkyl)(C_3-C_8 cycloalkyl), -O-(C_3-C_8 cycloalkyl), heterocycloalkyl, (C_1-C_3 alkyl)(heterocycloalkyl), -O-(heterocycloalkyl), C_6-C_{10} aryl, (C_1-C_3 alkyl)(C_6-C_{10} aryl), -O-(C_6-C_{10} aryl), heteroaryl, (C_1-C_3 alkyl)(heteroaryl), or –O-

(heteroaryl), wherein each alkyl is substituted with 0, 1, 2, 3, 4, 5, or 6 R^{3c}, each alkoxy is substituted with 0, 1, 2, or 3 R^{3d}, and each cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is substituted with 0, 1, 2, or 3 R^{3e}; or,

two R^3 on the same carbon atom together represent an oxo group;

each R^{3a} and R^{3b} is independently hydrogen or C_1-C_6 alkyl;

each R^{3c} is independently C_1-C_6 alkoxy, halogen, C_1-C_6 haloalkoxy, -$NR^{3c1}R^{3c2}$, -OH, or -CN;

each R^{3c1} and R^{3c2} is independently hydrogen or C_1-C_6 alkyl;

each R^{3d} is independently C_3-C_8 cycloalkyl, heterocycloalkyl, phenyl, or heteroaryl;

each R^{3e} is independently C_1-C_6 alkyl, C_1-C_6 alkoxy, halogen, C_1-C_6 haloalkyl, or C_1-C_6 haloalkoxy;

R^4 is hydrogen or C_1-C_6 alkyl;

subscript n is 0, 1, 2, 3, or 4; and




subscript q is 0, 1, 2, 3, or 4;











wherein











each heterocycloalkyl is a 3- to 8-membered ring that includes 1 to 4 heteroatoms each independently N, O or S; and








each heteroaryl is a 5- to 6-membered ring that includes 1 to 4 heteroatoms each independently N, O or S.

21. The compound of claim 20, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the following compounds:

No.	Structure	Name
232		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-(2-methoxyphenylsulfonimidoyl)picolinamide
243		5-((1H-pyrazol-1-yl)methyl)-N-(2,6-dimethoxyphenylsulfonimidoyl)-6-methoxypicolinamide
260		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-(2-methoxy-6-(2,2,2-trifluoroethoxy)phenylsulfonimidoyl)picolinamide

No.	Structure	Name
261		5-((1H-pyrazol-1-yl)methyl)-N-(2-cyclobutoxy-6-methoxyphenylsulfonimidoyl)-6-methoxypicolinamide
262		5-((1H-pyrazol-1-yl)methyl)-N-(2,4-dimethoxyphenylsulfonimidoyl)-6-methoxypicolinamide
263		5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-(2,4,6-trimethoxyphenylsulfonimidoyl)picolinamide
290a		(R)-5-((1H-pyrazol-1-yl)methyl)-N-(5-(1-hydroxy-2-methylpropan-2-yl)-2-methoxyphenylsulfonimidoyl)-6-methoxypicolinamide
290b		(S)-5-((1H-pyrazol-1-yl)methyl)-N-(5-(1-hydroxy-2-methylpropan-2-yl)-2-methoxyphenylsulfonimidoyl)-6-methoxypicolinamide
293a		(R)-5-((1H-pyrazol-1-yl)methyl)-N-(3-chloro-2,6-dimethoxyphenylsulfonimidoyl)-6-methoxypicolinamide
293b		(S)-5-((1H-pyrazol-1-yl)methyl)-N-(3-chloro-2,6-dimethoxyphenylsulfonimidoyl)-6-methoxypicolinamide
294		5-((1H-pyrazol-1-yl)methyl)-N-(2-ethoxy-6-methoxyphenylsulfonimidoyl)-6-methoxypicolinamide
294a		(R)-5-((1H-pyrazol-1-yl)methyl)-N-(2-ethoxy-6-methoxyphenylsulfonimidoyl)-6-methoxypicolinamide
294b		(S)-5-((1H-pyrazol-1-yl)methyl)-N-(2-ethoxy-6-methoxyphenylsulfonimidoyl)-6-methoxypicolinamide

No.	Structure	Name
296a		(R)-5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-(2,4,6-trimethoxyphenylsulfonimidoyl)picolinamide
296b		(S)-5-((1H-pyrazol-1-yl)methyl)-6-methoxy-N-(2,4,6-trimethoxyphenylsulfonimidoyl)picolinamide
297		5-((1H-pyrazol-1-yl)methyl)-N-(5-(2-hydroxypropan-2-yl)-2-methoxyphenylsulfonimidoyl)-6-methoxypicolinamide
298a		(R)-5-((1H-pyrazol-1-yl)methyl)-N-(2-cyclobutoxy-6-methoxyphenylsulfonimidoyl)-6-methoxypicolinamide
298b		(S)-5-((1H-pyrazol-1-yl)methyl)-N-(2-cyclobutoxy-6-methoxyphenylsulfonimidoyl)-6-methoxypicolinamide
301a		(R)-5-((1H-pyrazol-1-yl)methyl)-N-(2,6-dimethoxy-3-methylphenylsulfonimidoyl)-6-methoxypicolinamide
301b		(S)-5-((1H-pyrazol-1-yl)methyl)-N-(2,6-dimethoxy-3-methylphenylsulfonimidoyl)-6-methoxypicolinamide
303a		(R)-5-((1H-pyrazol-1-yl)methyl)-N-(2,3-dihydrobenzofuran-7-sulfonimidoyl)-6-methoxypicolinamide
303b		(S)-5-((1H-pyrazol-1-yl)methyl)-N-(2,3-dihydrobenzofuran-7-sulfonimidoyl)-6-methoxypicolinamide
305a		(R)-5-((1H-pyrazol-1-yl)methyl)-N-(2-fluoro-6-methoxyphenylsulfonimidoyl)-6-methoxypicolinamide

No.	Structure	Name
305b		(S)-5-((1H-pyrazol-1-yl)methyl)-N-(2-fluoro-6-methoxyphenylsulfonimidoyl)-6-methoxypicolinamide
306a		(R)-5-((1H-pyrazol-1-yl)methyl)-N-(2,6-dimethoxy-4-methylphenylsulfonimidoyl)-6-methoxypicolinamide
306b		(S)-5-((1H-pyrazol-1-yl)methyl)-N-(2,6-dimethoxy-4-methylphenylsulfonimidoyl)-6-methoxypicolinamide
307a		(R)-5-((1H-pyrazol-1-yl)methyl)-N-(2-fluorophenylsulfonimidoyl)-6-methoxypicolinamide
307b		(S)-5-((1H-pyrazol-1-yl)methyl)-N-(2-fluorophenylsulfonimidoyl)-6-methoxypicolinamide
308a		(R)-5-((1H-pyrazol-1-yl)methyl)-N-(2,6-difluorophenylsulfonimidoyl)-6-methoxypicolinamide
308b		(S)-5-((1H-pyrazol-1-yl)methyl)-N-(2,6-difluorophenylsulfonimidoyl)-6-methoxypicolinamide

.

22. A pharmaceutical composition comprising a compound of any one of claims 1 to 21 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

23. A compound according to any one of claims 1 to 21 or a pharmaceutically acceptable salt thereof, for use as a medicament.

24. Use of a compound according to any one of claims 1 to 21 or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament.

25. Use of a compound according to any one of claims 1 to 21 or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for modulating KAT6A.

26. Use of a compound according to any one of claims 1 to 21 or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating a disease or disorder mediated by KAT6A.

27. The use of claim 26, wherein the disease or disorder is cancer.

28. The use of claim 27, wherein the cancer is selected from brain gliomas, glioblastomas, astrocytomas, multiforme, Bannayan-Zonana syndrome, Cowden disease, Lhermitte-Duclos disease, breast cancer, colon cancer, head and neck cancer, kidney, liver, lung cancer, bone cancer, colorectal cancer, germ cell cancer, melanoma, ovarian cancer, pancreatic cancer, adenocarcinoma, ductal adenocarcinoma, adenosquamous carcinoma, acinar cell carcinoma, glucagonoma, insulinoma, prostate, sarcoma and thyroid cancer, lymphoblastic T cell leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, hairy-cell leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia, chronic neutrophilic leukemia, acute lymphoblastic T cell leukemia, plasmacytoma, immunoblastic large cell leukemia, mantle cell leukemia, megakaryoblastic leukemia, multiple myeloma, acute megakaryocytic leukemia, promyelocytic leukemia, erythroleukemia, malignant lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, lymphoblastic T cell lymphoma, Burkitt's lymphoma, follicular lymphoma, neuroblastoma, bladder cancer, urothelial cancer, vulval cancer, uterine cancer, cervical cancer, endometrial cancer, renal cancer, mesothelioma, esophageal cancer, salivary gland cancer, hepatocellular cancer, gastric cancer, nasopharyngeal cancer, buccal cancer, cancer of the mouth, gastrointestinal stromal tumor, neuroendocrine cancers, testicular cancer, and virus-related cancer.

29. Use of a compound according to any one of claims 1 to 21 or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use in combination with an additional anti-cancer agent.

30. The use of claim 29, wherein the additional anti-cancer agent is selected from a HER2 inhibitor, an pmTOR inhibitor, a CDK4/6 inhibitor, a CDK2-selective inhibitor, a CDK4-selective inhibitor, a PI3 kinase inhibitor, a PIK3CA inhibitor, an aromatase inhibitor, an antibody to or inhibitor of PD-1, PD-L1 or CTLA-4, an antibody to or inhibitor of EGFR, PGFR, or IGFR, a USP inhibitor, or an AKT inhibitor.

31. Use of a compound according to any one of claims 1 to 21 or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use in combination with an estrogen receptor antagonist or an estrogen receptor partial antagonist.